Hypoglycaemia is reduced with use of inhaled Technosphere ® Insulin relative to insulin aspart in type 1 diabetes mellitus
نویسندگان
چکیده
منابع مشابه
Technosphere Inhaled Insulin: Is Faster Better?
Pulmonary-delivered insulin is again a reality (1). The failure of the first inhaled insulin in 2007 showed that being radically different from what health care providers are used to, even when injections are avoided, can be problematic. The current product Technosphere inhaled insulin has addressed many of the prior concernsda more convenient delivery device that is dosed in insulin units. Als...
متن کاملInhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial.
OBJECTIVE To compare the efficacy and safety of Technosphere insulin (TI) and insulin aspart in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS This open-label noninferiority trial compared the change in HbA1c from baseline to week 24 of prandial TI (n = 174) with that of subcutaneous aspart (n = 171), both with basal insulin, in patients with type 1 diabetes and HbA1c 7.5-10.0% (5...
متن کاملInhaled insulin in diabetes mellitus.
BACKGROUND Insulin therapy often relies on multiple daily injections of insulin. However this is a considerable burden to many people with diabetes and adherence to such an insulin regimen can be difficult to maintain, hence compromising optimal glycaemic control. Also, short acting injected insulin is absorbed more slowly than insulin released by the normal pancreas in response to a meal. Inha...
متن کاملImmune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes.
OBJECTIVE The antibody responses to a novel rapid-acting insulin analog, insulin aspart (IAsp), and their potential clinical correlates were studied with a specifically developed method in 2,420 people with diabetes treated for up to 1 year with preprandial subcutaneous injections of IAsp. RESEARCH DESIGN AND METHODS Circulating insulin antibodies were analyzed by radioimmunoassay with (125)I...
متن کاملPlace of technosphere inhaled insulin in treatment of diabetes
Technosphere insulin (TI), Afrezza, is a powder form of short-acting regular insulin taken by oral inhalation with meals. Action of TI peaks after approximately 40-60 min and lasts for 2-3 h. TI is slightly less effective than subcutaneous insulin aspart, with mean hemoglobin A1c (HbA1c) reduction of 0.21% and 0.4%, respectively. When compared with technosphere inhaled placebo, the decrease in ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetic Medicine
سال: 2019
ISSN: 0742-3071,1464-5491
DOI: 10.1111/dme.14202